TITLE

HIV patients live years after diagnosis

PUB. DATE
November 2006
SOURCE
Gay & Lesbian Times;11/16/2006, Issue 986, p28
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the results of a research which show that an American diagnosed with the AIDS virus can expect to live for about 24 years on average. The research also shows that the cost of health care throughout those decades is more than $600,000. Bruce Schackman is the lead author of the study.
ACCESSION #
23886113

 

Related Articles

  • HIV patients live years after diagnosis.  // Gay & Lesbian Times;12/28/2006, Issue 992, p39 

    The article reports that a research conducted in the U.S. has revealed that an American diagnosed with AIDS virus is expected to live for about 24 years on average, and that the cost of his health care throughout his expected existence is estimated to be more than $600,000. According to the...

  • Early HIV treatment cost-effective in resource-limited settings.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p825 

    The article reports on a study by Bruce R. Schackman and colleagues at Weill Cornell Medical College which compare the cost effectiveness in early and standard antiretroviral treatment (ART) for HIV cases based on the data from a randomized clinical trial in Haiti.

  • Coping with the cost burdens of illness: Combining qualitative and quantitative methods in longitudinal, household research. Goudge, Jane; Gumede, Tebogo; Gilson, Lucy; Russell, Steve; Tollman, Stephen M.; Mills, Anne // Scandinavian Journal of Public Health;May2007 Supplement 69, Vol. 35 Issue s69, p181 

    Over the last 10-15 years, poor African households have had to cope with the burden of increased levels of chronic illness such as HIV/AIDS. How do these households cope with the cost burdens of ill health and healthcare, and has this burden further impoverished them? What policy responses might...

  • State AIDS Drug Assistance Programs Continue to Face Difficult Funding Challenges; 11 States Close Enrollment, 9 Have Waiting Lists to Receive HIV Drugs; Wide Variation in Access to HIV...  // Ascribe Newswire: Medicine;5/20/2004, p165 

    Despite a 9 percent increase in the overall AIDS Drug Assistance Programs (ADAPs) budget in the U.S. between fiscal year 2002 and 2003, an increasing number of people living longer with HIV/AIDS, the rising costs of HIV medications, and continuing fiscal pressures at the Federal and state levels...

  • Cost effectiveness of prophylaxis for opportunistic infections in AIDS. An overview and methodological discussion. Freedberg, K.A.; Paltiel, A.D. // PharmacoEconomics;1998, Vol. 14 Issue 2, p165 

    Dramatic progress has recently been made in defining the pathogenesis and treatment of HIV infection. For the first time in the history of the AIDS epidemic, clinicians have at their disposal an understanding of the replication kinetics of HIV, reliable assays to measure viral load, an...

  • Analysis of Michigan Medicaid Costs to Treat HIV Infection. Solomon, David J.; Hogan, Andrew J.; Bouknight, Reynard A.; Solomon, Carolyn T. // Public Health Reports;Sep/Oct89, Vol. 104 Issue 5, p416 

    To obtain better understanding of the nature and cost of health care related to human immunodeficiency virus (HIV) infection, medical payment records were analyzed for 204 men, women, and children older than 60 months who had indications of HIV infection. The records were those of Michigan...

  • Financing Health Care for Persons with HIV Infection: Guidelines for State Action. Fox, Daniel M. // American Journal of Law & Medicine;1990, Vol. 16 Issue 1/2, p223 

    Promises of confidentiality of HIV-related medical records and protection from discrimination based on HIV seropositivity are two of the legislative inducements state governments have offered to encourage voluntary HIV testing. Yet neither can be granted without impact on others whose interests...

  • Value of nevirapine for preventing MTCT of HIV infections in Africa.  // PharmacoEconomics & Outcomes News;8/14/2004, Issue 459, p11 

    Discusses research being done on the cost effectiveness of nevirapine treatment for the prevention of mother-to-child transmission of HTV infections across African countries. Reference to a study by M. D. Sweat, et al published in the August 2004 issue of "AIDS"; Number of HIV infections...

  • Health Economics in HIV Disease: A Review of the European Literature. Youle, M.; Trueman, P.; Simpson, K. // PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1 

    The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics